{
    "nct_id": "NCT04284761",
    "official_title": "A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer",
    "inclusion_criteria": "* Histologically confirmed adenocarcinoma of the prostate.\n* Study participant qualified and planning for radical prostatectomy.\n* At least 1 prostate lesion measurable by MRI > 0.5 cm within one month of screening.\n* PSA > 3 ng/mL within 3 months of screening.\n* Gleason score 3+4 or higher.\n* Study participant must be willing to undergo post-treatment imaging by MRI.\n* ECOG performance status 0 or 1.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 35 Years",
    "exclusion_criteria": "* Prior radiotherapy or surgery for prostate cancer.\n* Prior or ongoing hormonal therapy for prostate cancer.\n* Prior prostate procedures such as transurethral resection of the prostate, transurethral microwave thermotherapy of the prostate, high-intensity focused ultrasound or minimally invasive BPH procedure.\n* Study participant unwilling or unable to undergo MRI, including patients with contra-indications to MRI, such as cardiac pacemakers, non-compatible intracranial vascular clips, etc.\n* Metallic hip implant or any other metallic implant or device that distorts the quality of prostatic MR images.\n* Use of 5 alpha reductase inhibitors (e.g. Finasteride or Dutasteride) within 3 months of screening or total use within the last two years prior to screening of > 3 months.\n* Presence of any metastatic disease.\n* Prostate volume more than 80 cc at prior MRI imaging.\n* I-PSS score >20.\n* History of prostate infection.",
    "miscellaneous_criteria": ""
}